![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1409920
ÀÚ°¡Åõ¿© ÁÖ»ç ¸é¿ªÄ¡·áÁ¦ : Á¦Ç°, Ä¡·áÁ¦, ½ÃÀå, Àü·«Self-administered Injectable Immune Therapeutics, Products, Therapeutics, Markets & Strategies |
Ç×ü ÀǾàǰ°ú ±× Èĺ¸¹°ÁúÀÇ ±Þ°ÝÇÑ Áõ°¡¿¡ ÈûÀÔ¾î »ý¹°ÇÐÀû Á¦Á¦´Â °³¹ß ÆÄÀÌÇÁ¶óÀΰú ÀÓ»ó½ÃÇè¿¡¼ ´Ù¸¥ ¸ðµç NCE¸¦ °è¼Ó ´É°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀúºÐÀÚ ÀǾàǰÀ¸·ÎÀÇ ÀüȯÀº ÀǾàǰ °³¹ßÀÚ, ÀÇ·á±â±â ¼³°èÀÚ, Æ÷Àå ´ã´çÀÚ, ±×¸®°í ÀǾàǰ ¸¶ÄÉÆÃ ´ã´çÀÚ¿¡°Ô ºñÁö´Ï½º ±âȸ¸¦ °¡Á®´ÙÁÖ°í ÀÖ½À´Ï´Ù.
»ý¹°ÇÐÀû Á¦Á¦´Â ¸¸¼º ÁúȯÀ» ´ë»óÀ¸·Î ÇÏ´Â °æ¿ì°¡ ¸¹±â ¶§¹®¿¡ Åõ¿© Àü·«°ú Ä¡·á ÇÁ·ÎÅäÄÝÀº Àå±âÀûÀÎ »ç¿ëÀ» °ßµô ¼ö ÀÖµµ·Ï °³¹ßµÇ¾î¾ß Çϸç, ¸¹Àº °æ¿ì º´°ú Á÷Á¢ÀûÀ¸·Î ¿¬°üµÈ Á¦ÇÑÀ» ¹ÞÀ» ¼ö Àִ ȯÀÚÀÇ ÀÚ°¡ Áֻ縦 À§ÇØ °³¹ßµÇ¾î¾ß ÇÕ´Ï´Ù. ÇâÈÄ 5³â µ¿¾È ÀǾàǰ °³¹ßÀÚµéÀÌ ¸¸¼ºÁúȯ ȯÀÚ Áõ°¡¿¡ ´ëÀÀÇϱâ À§ÇØ ÀÏȸ¿ë ¹× ´Ùȸ¿ë ¹ÙÀ̾˿¡¼ ÇÁ¸®Çʵå ÁÖ»ç±â·ÎÀÇ Æ÷Àå ÀüȯÀÌ °¡¼Ó鵃 °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ, Ç×ü, È£¸£¸ó ¹× ±âŸ »ý¹°ÇÐÀû ¾à¹°ÀÇ °·ÂÇÑ »ý¸®Àû ÀÛ¿ëÀ¸·Î ÀÎÇØ ¾ÈÀü ¹× ±ÔÁ¤ Áؼö¿¡ ´ëÇÑ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.
¼¼°èÀÇ ÀÚ°¡Åõ¿© ÁÖ»ç ¸é¿ªÄ¡·áÁ¦ ½ÃÀå¿¡ ´ëÇØ ºÐ¼®ÇßÀ¸¸ç, Á¦Ç° °³¿ä¿Í ÁÖ¿ä Á¾·ù, ½ÃÀå ±âº» ±¸Á¶¿Í ÁÖ¿ä ÃËÁø¡¤¾ïÁ¦¿äÀÎ, ÁÖ¿ä ±â¾÷ÀÇ ÇâÈÄ(-2028³â) °³¹ß Àü·«°ú ±× ¿µÇâ¿äÀÎ, ÀÚ°¡Åõ¿© ÁÖ»ç ¸é¿ªÄ¡·áÁ¦ °³¹ß ¹× Á¦Á¶ ¿¡ÄڽýºÅÛ, ÇâÈÄ Á¦Ç° ¼±ÅÃÀÇ ÁÖ¿ä °æÁ¦Àû, ±â¼úÀû, ±ÔÁ¦Àû ¿äÀÎ µîÀÇ Á¤º¸¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
Therapeutics is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector.
The study is designed to provide drug company decision makers, drug delivery developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, disease segments, and commercial opportunities for therapeutic biological drugs. Provider organization business managers, healthcare administrators and investors will also benefit from this study.
Led by the proliferation of antibody-based drugs and candidates, biological drugs as a class continue to outpace all other NCEs in development pipelines and clinical trials. This shift away from small molecule drugs is creating opportunities for drug developers, device designers, packagers and - ultimately - pharmaceutical marketers.
Because biological drugs most often target chronic conditions, dosing strategies and treatment protocols must be developed for long-term use, often for self-administration by patients who may have limitations directly related to their condition. The shift in as-supplied packaging from single and multi-use vials to prefilled injection devices will accelerate over the next five years as drug developers move to empower an increasing number of chronically ill patients. The powerful physiological effects of antibodies, hormones and other biological drugs also increase the need for safety and compliance.